About 25 years ago the addition of the combination of mitoxantrone + prednisone to androgen deprivation therapy (ADT) was the first form of chemotherapy ever approved for the treatment of metastatic, castration-resistant prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "high risk", ADT, androgen, deprivation, mitoxantrone, outcome, prednisone, survival | 3 Comments »
The appropriate, individual treatment of men with metastatic and non-metastatic forms of castration-resistant prostate cancer (CRPC) has become vastly more complicated over the past 5 years. … READ MORE …
Filed under: Management, Treatment | Tagged: castration-resistant, CRPC, estramustine, mitoxantrone, Treatment | Leave a comment »
A report on a Phase II study from the Department of Defense-funded Prostate Cancer Clinical Trials Consortium has suggested that ixabepilone + mitoxantrone + prednisone may have clinically significant activity as a form of second-line chemotherapy in the management of men with docetaxel-refractory, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ixabepilone, mCRPC, mitoxantrone, prednisone, taxane-refractory | 2 Comments »
According to a media release from Sanofi-Aventis early this morning, the second-generation taxane cabazitaxel, when given in combination with prednisone, is capable of extending median survival by 2.4 months compared to mitoxantrone + prednisone in prostate cancer patients who are refractory to docetaxel (Taxotere) chemotherapy. … READ MORE …
Filed under: Drugs in development | Tagged: cabazitaxel, CRPC, docetaxel, mitoxantrone | 3 Comments »
In today’s news reports you will find items on:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: EBRT, external beam radiation therapy, mitoxantrone, obesity, outcome, prednisone, PSA level | Leave a comment »
In today’s news reports we discuss:
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: chemotherapy, expression, gene, ginger, intermediate, ixabepilone, mitoxantrone, nausea, risk | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 